CIO Bulletin Announces DiaCarta Inc. As One of the 30 Fastest Growing Companies of 2018
RICHMOND, Calif.–(BUSINESS WIRE)–DiaCarta today announced that CIO Bulletin has named it among the 30 Fastest Growing Companies of 2018. The positioning is based on DiaCarta’s revenue growth, financial status, openness to innovation, global collaboration and partnership, flagship products launching, regulatory progress and ability to forecast future business and technology trends. Selecting by a panel of experts and members of CIO Bulletin’s editorial board, the CIO Bulletin 30 Fastest Growing Companies of 2018 is a premier recognition program which identifies companies that have the most innovative approach towards understanding the market trends and exceptional problem-solving techniques in the field of Business and Technology.
“We are glad to name DiaCarta as one of the 30 fastest growing companies of 2018. Realizing a total of $45.0 M USD through its Series B funding round, DiaCarta has made several milestones in the year of 2018 for its development and commercialization of the precision molecular diagnostics products (CE only), including liquid biopsy single gene mutation detection tests, colorectal cancer mutation detection blood test, blood-based radiation therapy toxicity monitoring test, HPV mRNA test, etc. and all the clinical developments,” said J. P. Pande, Editor-in-Chief of the CIO Bulletin Magazine.
“We are honored and thrilled to be recognized by CIO Bulletin as one of the 30 Fastest Growing Companies of 2018,” said Aiguo (Adam) Zhang, CEO and Founder of DiaCarta, “We are moving our business to the next level by putting our flagship products to clinical trials in the U.S., China, and Italy in 2019 and looking forward to serving cancer diagnostic and therapeutic community with our innovations that redefine precision molecular diagnostics.”
DiaCarta is a translational genomics and personalized diagnostics company based in Richmond, California with significant business operations in China. DiaCarta provides highly sensitive and advanced technologies in molecular diagnostics and clinical genomics. With over 20,000 square feet dedicated to a GMP-compliant lab space as well as CLIA and ISO 13485 certifications, DiaCarta is changing the landscape of molecular diagnostics.
ABOUT CIO BULLETIN
CIO Bulletin is an interactive, preeminent leadership platform serving as a central resource for information on Business & Information Technology (IT) leaders and their entrepreneurial ventures. From celebrating innovation to identifying best practices and providing a forum for today’s CIOs and other technology decision makers, CIO Bulletin aspires to keep its readers informed about how the techie giants, governments and consumers are unfurling organizational innovation in the Business & IT world.
DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology and infectious disease tests announced today that the company has received CE-IVD mark for their newly developed QuantiVirus™ SARS-CoV-2 & Flu A/B Test.
DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology tests using liquid biopsy, today announced the appointment of Jack Kaye, retired Partner with Deloitte LLP, as an independent board member who will serve as the Chairman of the Company’s Audit Committee.
DiaCarta Enters a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to Develop Cancer Tests based on its Novel XNA Technology
DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology tests using liquid biopsy today announced that the company, under a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health, will collaborate on the evaluation and development of DiaCarta’s proprietary xeno-nucleic acid (XNA) molecular clamping technology. NCI and DiaCarta will collaborate on the following projects: (1) the investigation of low frequency mutation events in cancers and rare diseases using DiaCarta’s proprietary xeno-nucleic acid (XNA) molecular clamping technology, and (2) the development of XNA probes for in situ cancer cell detection. The duration of the CRADA will be 2 years from the effective start date.
DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology tests using liquid biopsy announced today that the company has developed a novel test to detect the newest COVID-19 Omicron variant, based on its proprietary XNA technology.
DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel virology and oncology tests, mourns the passing of Michael “Mike” J. Powell, Ph.D., Chief Scientific Officer of DiaCarta.